The table below shows ImmunityBio, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$113.29M
$14.74M
$622.00K
$240.00K
$934.00K
$605.00K
Cost of revenue
$753.00K
$0.00
$0.00
$0.00
-
-
Gross profit
-
-
-
-
-
-
R&D
-
$190.14M
$232.37M
$248.15M
$195.96M
$139.51M
SG&A
IBRX annual revenue (10-K history)
ImmunityBio, Inc. reported annual revenue of $113.29M for fiscal year 2025. That is up 668.3% from $14.74M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $44.00K (FY 2016) to $113.29M. Figures come from the company's audited annual reports as filed with the SEC.